(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 11.91% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 5.29%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.62%.
Neogenomics's revenue in 2025 is $660,566,000.On average, 7 Wall Street analysts forecast NEO's revenue for 2025 to be $94,831,734,467, with the lowest NEO revenue forecast at $94,431,962,643, and the highest NEO revenue forecast at $95,138,500,250. On average, 7 Wall Street analysts forecast NEO's revenue for 2026 to be $105,590,375,293, with the lowest NEO revenue forecast at $103,950,951,124, and the highest NEO revenue forecast at $106,563,855,654.
In 2027, NEO is forecast to generate $118,870,841,529 in revenue, with the lowest revenue forecast at $117,555,011,583 and the highest revenue forecast at $119,806,939,627.